Table of contents
- Coronavirus (COVID-19)
- Coronavirus (COVID-19)—Government launches adverse side effect reporting website
- EMA fast-tracks marketing authorisations for coronavirus (COVID-19) medicines
- EMA updates guide on safety reports adding coronavirus (COVID-19) related terms
- Emergency measures for supply of controlled drugs clarified amid coronavirus (COVID-19)
- EMA launches rolling review of trial antiviral medicine amid coronavirus (COVID-19) outbreak
- New reagent available worldwide to support testing of coronavirus (COVID-19)
- Coronavirus (COVID-19)—EU Executive Steering Group update
- Contact tracing app launched to curb spread of coronavirus (COVID-19)
- Intellectual property
More sections of this document available when you sign-in to Lexis+ or register for a free trial.
Article summary
This week's edition of Life Sciences weekly highlights includes the latest coronavirus (COVID-19) developments, analysis of the Court of Justice’s judgment in Royalty Pharma Collection Trust which restricts the types of patents that can be used as the basis for SPCs, and news that the EMA has issued guidance on the follow-up procedure of pharmacovigilance inspections.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial
Access this content for free with a 7 day trial of LexisNexis and benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 42 practice areas
Get your quote today and take step closer to being able to benefit from:
- Instant clarification on points of law
- Smart search
- Workflow tools
- 36 practice areas
Get a quote for Lexis+
* denotes a required field
CONTACT US
